TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

BACKGROUND: TRK inhibitors achieve marked tumor-agnostic efficacy in TRK fusion-positive cancers and consequently are now an established standard of care. Little is known, however, about the demographics, outcomes, response to alternative standard therapies, or genomic characteristics of TRK fusion-...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Rosen, Ezra Y., Goldman, Debra A., Hechtman, Jaclyn F., Benayed, Ryma, Schram, Alison M, Cocco, Emiliano, Shifman, Sophie, Gong, Yixiao, Kundra, Ritika, Solomon, James P., Bardelli, Alberto, Scaltriti, Maurizio, Drilon, Alexander, Iasonos, Alexia, Taylor, Barry S., Hyman, David M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7124988/
https://ncbi.nlm.nih.gov/pubmed/31871300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3165
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky